Gonorrhea Treatment When the Partner Can’t Be Reached
A likely gonorrhea diagnosis, current guidance favoring a single drug, and a partner whose status is genuinely unknown rather than reassuringly clear. The gap is testable, not just arguable.
Jasmine T., a 26-year-old graduate student, came to the sexual health clinic with vaginal discharge and mild pelvic discomfort over the past several days, and point-of-care testing along with clinical presentation strongly support gonococcal infection, with formal culture and NAAT results still pending at the time of her visit. She has been in a relationship for the past four months with a partner currently traveling out of the country for work, reachable only sporadically, and she has no way to know whether he has been tested or treated for anything — a genuine gap rather than a hypothetical one, since public health partner notification hasn’t yet been able to reach him either.
Current CDC guidance, updated in 2020, moved away from routinely co-treating gonorrhea with azithromycin for presumed chlamydia coinfection, treating ceftriaxone as effective monotherapy for gonorrhea specifically and reserving chlamydia treatment for confirmed or strongly suspected coinfection — a change made deliberately to reduce unnecessary azithromycin exposure and the resistance pressure it places on Neisseria gonorrhoeae, an organism with a well-documented history of acquiring resistance to whatever is used against it most. She has no known chlamydia exposure history of her own, but her partner’s status is genuinely unknown rather than reassuringly negative, which is the specific gap the team is weighing against the stewardship rationale behind current guidance.
The 2020 policy shift was itself a direct response to surveillance data showing gonococcal isolates with reduced azithromycin susceptibility rising steadily across the years dual therapy was standard practice — evidence that treating an organism with a second drug it doesn’t need, purely as insurance against an unconfirmed coinfection, has a real population-level cost that eventually lands on patients much like her. That history is why nobody in the room wants to treat "we don’t know her partner’s status" as automatic grounds to revert to the older combined approach. What none of them can answer is what happens if her NAAT is negative and her partner, whenever he is finally reached, is not — whether the forty-eight hours saved by treating presumptively today would have mattered to her at all, or only to the resistance curve everyone is trying to protect.
Sexual health clinic, same-day visit
Ceftriaxone monotherapy is the current standard, and I don’t think we should quietly revert to routine co-treatment just because her partner status is unknown. The 2020 guideline change happened specifically because Neisseria gonorrhoeae keeps developing resistance to whatever we throw at it, and unnecessary azithromycin exposure across the population is exactly what accelerates that. Treat the infection she actually has.
I take the resistance argument seriously, but I want to name the individual risk in front of us honestly — her partner isn’t confirmed negative, he’s genuinely untestable right now, which is a real gap, not a hypothetical one. Untreated chlamydia carries its own reproductive-health consequences if it’s actually present and missed. The population-level stewardship argument doesn’t fully answer what to do about her specific, uncertain exposure.
This doesn’t need to be argued from guidance on either side — it’s directly testable. We already sent a chlamydia NAAT today; results are back in a day or two. Treat gonorrhea with ceftriaxone now, hold doxycycline, and add it the moment her own result comes back positive rather than presumptively treating an exposure we can actually just confirm or rule out.
Agreed: ceftriaxone given today, chlamydia NAAT result to determine doxycycline directly rather than treating on assumption in either direction; she was counseled to return or be reachable by phone for results within 48 hours.
Her NAAT returned positive for chlamydia two days later; doxycycline was added by phone with a prescription sent to her pharmacy, and public health partner notification remained ongoing separately for her partner.